To address knowledge gaps, investigators conducted a meta-analysis of more than 70,000 patients in 10 trials of SGLT2 inhibitors vs placebo to determine the relative risks of CKD progression across ...

The phase 2 EXPLORE-CKD trial is examining the efficacy and safety of lorundrostat in addition to SGLT2 inhibitors in patients with hypertension and CKD with albuminuria.

Expanding the wait-listing criteria for kidney transplantation to include risk for kidney failure -- rather than taking a ...

Enrollment ongoing in Phase 2 KOURAGE trial of Auxora in acute kidney injury (AKI) with respiratory failure; data expected in 1H 2026 Positive discussions with FDA ...

DBM Global delivers robust revenue growth, reinforcing market leadership -- Life Sciences: MediBeacon received regulatory ...

Discover INNOVATE Corp.’s Q3 2025 earnings highlights: strong revenue growth, expanding backlog, and strategic updates.

Social Security’s cost-of-living adjustment is expected to be as much as 2.8% in 2026, analysts said, but the average $54 monthly increase may not go very far as inflation creeps higher. According to ...

CalciMedica Inc. ("CalciMedica" or the "Company") , a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for ...

In January 2026, several changes to Social Security will take effect, impacting everything from credits and taxes to benefit checks and full retirement age (FRA) rules. These changes don't only impact ...